Eptifibatide
Cardiovascular & vascular
Large acute coronary syndrome and PCI research includes PURSUIT, in which eptifibatide reduced the 30 day composite of death or nonfatal MI but increased bleeding.
An authorisation applies to at least one defined finished product in a stated jurisdiction; it does not apply automatically to this catalogue material.
What is Eptifibatide?
Eptifibatide is a cyclic peptide GPIIb/IIIa antagonist derived from venom peptides used in platelet aggregation and cardiovascular research; the catalogue entry denotes the research grade cyclic peptide.
Which research context has Eptifibatide been associated with?
Eptifibatide is associated with cardiovascular research as a cyclic heptapeptide antagonist of platelet GPIIb/IIIa integrin, extensively studied in acute coronary syndrome and percutaneous coronary intervention trials such as PURSUIT, with haemostasis and bleeding risk endpoints.
What documentation is available for Eptifibatide?
Eptifibatide: Batch documents are not yet linked on this site. For this cyclic heptapeptide GPIIb/IIIa antagonist the checklist includes batch identifier and release date; identity by liquid chromatography mass spectrometry/intact mass and sequence or cyclic confirmation; analytical HPLC/UPLC chromatogram with method and purity specification; peptide content, counterion and residual solvent/water data; and assay/potency used for release. No batch documentation is shown as available until the record for that specific item is linked and reviewed.
What determines the storage conditions for Eptifibatide?
Eptifibatide: Storage depends on the documented supplied presentation; as a cyclic heptapeptide verify dry/lyophilised or solution supply, counterion and concentration, solvent or buffer composition, pH, container closure compatibility and the integrity of the cyclic conformation including oxidation or conformational stability that may affect activity. No storage instruction is shown as available until the stability record for that specific item is linked and reviewed.